Full-Time

Life Sciences Strategy Consultant

ClearView Healthcare Partners

ClearView Healthcare Partners

501-1,000 employees

Life sciences strategy consulting for biopharma

Compensation Overview

$130k - $150k/yr

+ Annual discretionary performance bonus

New York, NY, USA

Hybrid

Hybrid work model with an expectation of working in the office 50% of the time.

Bachelor's, Master's

Category
Consulting (1)
Required Skills
SharePoint
Salesforce
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to ClearView Healthcare Partners

See people who can refer or advise you

Requirements
  • The candidate must independently manage activities across multiple workstreams and provide thought partnership on ambiguous or complex projects.
  • The candidate must have strong written and oral communication skills in English.
  • The candidate should be positioned to mentor junior team members.
  • The candidate must be proficient in the Microsoft Office Suite, including Outlook, Excel, and PowerPoint.
  • The candidate must seek support for more complex projects or difficult client situations.
  • The candidate must use a highly analytical and structured approach to solving complex problems.
  • The candidate must have an undergraduate or Master’s degree in the life sciences or equivalent.
  • The candidate must have at least three years of experience in life sciences consulting.
  • The candidate must demonstrate curiosity about business and healthcare strategy.
  • The candidate must have demonstrated leadership or initiative in any setting.
  • The candidate must work under a hybrid model with a 50% in-office expectation in the New York, Boston, or San Francisco office.
Responsibilities
  • The consultant will interact with clients and internal teams to address critical strategic questions in the biopharmaceutical space.
  • The consultant will conduct complex problem-solving through a hypothesis-based approach.
  • The consultant will create templated outputs to support project deliverables.
  • The consultant will conduct a straightforward project or workstream with moderate oversight.
  • The consultant will create and use analytic tools, such as forecast models, to support key decision-making.
  • The consultant will communicate recommendations to clients to inform strategy and maximize value.
Desired Qualifications
  • The candidate should have a bachelor’s degree.
  • The candidate should have familiarity with SharePoint and Salesforce.
  • The candidate should have previous experience in an administrative assistant or office support role.
  • The candidate should be willing to take on a range of tasks and work flexibly based on business need.
  • The candidate should have strong interpersonal skills and a desire to build relationships.
ClearView Healthcare Partners

ClearView Healthcare Partners

View

ClearView Healthcare Partners provides strategic consulting services exclusively for the life sciences sector, guiding pharmaceutical, biotechnology, medical devices, and diagnostics firms through decisions from discovery to commercialization. It completes project work with 100% of a dedicated team focused on a single client engagement, pairing rigorous scientific knowledge with business strategy, with many consultants holding life sciences PhDs. The firm differentiates itself through its strict one-client-per-project model, sector-only focus, and deep scientific expertise, plus international expansion to serve global clients. Its goal is to help life sciences companies grow, advance product development, and secure market access, creating value across the entire product lifecycle.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Newton, Massachusetts

Founded

2008

Get referred to ClearView Healthcare Partners

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ClearView invested $4 million in Epistemic AI on January 10, 2025.
  • The March 2026 Salesforce-driven expert-network overhaul improves screening, scheduling, and compensation.
  • Seven open roles and 2026 hiring across Boston, London, San Francisco, and Gurgaon signal demand.

What critics are saying

  • Epistemic AI integration exposes ClearView to expensive technology bets if adoption stalls.
  • Expert-network Salesforce changes in March 2026 can disrupt delivery and consultant utilization.
  • AI tools commoditize strategy decks, squeezing premium advisory pricing by 2027.

What makes ClearView Healthcare Partners unique

  • 100% dedicated project teams keep ClearView focused on one client engagement at a time.
  • PhD-heavy consultants and founders from McKinsey, Leerink, and banking anchor scientific credibility.
  • London and Zurich offices, opened by 2026, deepen cross-border biopharma coverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Remote Work Options

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Flexible Work Hours

Wellness Program

Mental Health Support

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Family Planning Benefits

Fertility Treatment Support

Home Office Stipend

Phone/Internet Stipend

Parental Leave

Adoption Assistance

Meal Benefits

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

12%
PR Newswire
Mar 12th, 2025
The Addf'S Diagnostics Accelerator Authors New Paper On Ocular Biomarker Landscape, Highlighting Ocular Tests As A Tool For Early Detection Of Alzheimer'S Disease

New findings published in Alzheimer's Dementia suggest blood biomarkers are expected to become the standard method for diagnosing Alzheimer's, while ocular tests offer a non-invasive alternative for detecting at-risk patient populations NEW YORK, March 12, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA) authored a first-of-its-kind paper, "Unlocking ocular biomarkers for early detection of Alzheimer's disease," providing a landscape review of ocular biomarkers as another tool, alongside blood biomarkers, to aid in the early detection of Alzheimer's disease. The paper, which was published in Alzheimer's Dementia, shares an informed perspective on the role of ocular biomarkers in the broader Alzheimer's diagnostics space and what defines a true ocular biomarker, while also highlighting the potential for ocular screening to identify at-risk patients who would otherwise go undiagnosed. The authors' assessment is based on hours of in-depth interviews with leading neurologists, ophthalmologists, optometrists, and primary care physicians from across the United States

Citybiz
Jan 13th, 2025
ClearView Invests $4M in Epistemic AI

ClearView Healthcare Partners announced a $4 million minority investment in Epistemic AI to enhance its EpistemicGPT platform, which combines AI with a vast biomedical knowledge graph. This partnership aims to improve ClearView's service offerings by integrating AI technology, enhancing research and drug development processes. The collaboration underscores a commitment to advancing biomedical research and healthcare outcomes through innovative technology solutions.

Citybiz
Jan 13th, 2025
ClearView Healthcare Partners Invest In Epistemic AI

BOSTON, MA and WESTPORT, CT – 13 January 2025: ClearView Healthcare Partners, the leading life sciences strategic consultancy supporting Pharma... Read More

Digital Therapeutics Alliance
Nov 15th, 2023
DTx Commercialization Launch Playbook Case Study

Digital Therapeutics Alliance is thrilled to announce the release of its latest white paper in collaboration with Clearview Healthcare Partners!

Foundation Fighting Blindness
Feb 13th, 2023
The Foundation's long-term impact on moving the inherited retinal disease field forward towards treatments and cures. — Foundation Fighting Blindness

The Foundation Fighting Blindness partnered with ClearView Healthcare Partners to evaluate the impact of its funding and resources since 2005 on the clinical understanding and development of novel therapies for inherited retinal diseases (IRDs).